Robert J. Motzer, a scholar from Memorial Sloan-Kettering Cancer Center in New York, USA, published a study comparing the efficacy of pazopanib versus sunitinib in the treatment of metastatic renal cell carcinoma in The NEW ENGLAND JOURNAL OF MEDICINE in 2014, which randomly assigned 1110 metastatic renal clear cell carcinoma cases equally to two groups, Group 1 with a total of 557 cases received pazopanib 800 mg/day, and group 2, a total of 553 cases, received sunitinib 50 mg/day for 4 weeks and stopped for 2 weeks. There were no significant differences in PFS and OS between the two groups. Drug side effects were compared: fatigue, 55% vs 63%; hand-foot syndrome, 29% vs 50%; thrombocytopenia, 41% vs 78%; and ALT elevation, 60% vs 43%. Pazopanib was more advantageous in terms of quality of life. This study confirmed that pazopanib and sunitinib had similar efficacy in the treatment of mRCC, but the safety and quality of life of the drugs were higher in the pazopanib group.